[1] Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822): 1245-1255.
[2] Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2): 69-90.
[3] Rankin S. Mesenchymal stem cells. Thorax. 2012;67(6): 565-566.
[4] Bissell MJ, Hines WC. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med. 2011;17(3): 320-329.
[5] Egeblad M, Nakasone ES, Werb Z. Tumors as organs: complex tissues that interface with the entire organism. Dev Cell. 2010;18(6): 884-901.
[6] Spaeth E, Klopp A, Dembinski J, et al. Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther. 2008;15(10): 730-738.
[7] Studeny M, Marini FC, Dembinski JL, et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst. 2004;96(21): 1593-1603.
[8] Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007;449(7162): 557-563.
[9] Tang Y, Wu X, Lei W, et al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med. 2009;15(7): 757-765.
[10] Schraufstatter IU, Discipio RG, Zhao M, et al. C3a and C5a are chemotactic factors for human mesenchymal stem cells, which cause prolonged ERK1/2 phosphorylation. J Immunol. 2009; 182(6): 3827-3836.
[11] Banas A, Yamamoto Y, Teratani T, et al. Stem cell plasticity: learning from hepatogenic differentiation strategies. Dev Dyn. 2007; 236(12): 3228-3241.
[12] Groth A, Ottinger S, Kleist C, et al. Evaluation of porcine mesenchymal stem cells for therapeutic use in human liver cancer. Int J Oncol. 2012;40(2): 391-401.
[13] Sun XY, Nong J, Qin K, et al. Mesenchymal stem cell-mediated cancer therapy: A dual-targeted strategy of personalized medicine. World J Stem Cells. 2011; 3(11): 96-103.
[14] Kalinina NI, Sysoeva VY, Rubina KA, et al. Mesenchymal stem cells in tissue growth and repair. Acta Naturae. 2011; 3(4): 30-37.
[15] Kidd S, Spaeth E, Dembinski JL, et al. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells. 2009;27(10): 2614-2623.
[16] Liu S, Ginestier C, Ou SJ, et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res. 2011;71(2): 614-624.
[17] Mclean K, Gong Y, Choi Y, et al. Human ovarian carcinoma-associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production. J Clin Invest. 2011;121(8): 3206-3219.
[18] Yan XL, Fu CJ, Chen L, et al. Mesenchymal stem cells from primary breast cancer tissue promote cancer proliferation and enhance mammosphere formation partially via EGF/EGFR/Akt pathway. Breast Cancer Res Treat. 2012;132(1): 153-164.
[19] Arendt LM, Rudnick JA, Keller PJ, et al. Stroma in breast development and disease. Semin Cell Dev Biol. 2010;21(1): 11-18.
[20] Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature. 2004;432(7015): 332-337.
[21] Bhowmick NA, Chytil A, Plieth D, et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science. 2004 ;303(5659): 848-851.
[22] Rhodes LV, Antoon JW, Muir SE, et al. Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk. Mol Cancer. 2010;9: 295.
[23] Halpern JL, Kilbarger A, Lynch CC. Mesenchymal stem cells promote mammary cancer cell migration in vitro via the CXCR2 receptor. Cancer Lett. 2011;308(1): 91-99.
[24] Tsai KS, Yang SH, Lei YP, et al. Mesenchymal stem cells promote formation of colorectal tumors in mice. Gastroenterology. 2011;141(3): 1046-1056.
[25] Duffy MM, Ritter T, Ceredig R, et al. Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Res Ther. 2011;2(4): 34.
[26] Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med. 2011;17(11): 1359-1370.
[27] Lin PP, Wang Y, Lozano G. Mesenchymal Stem Cells and the Origin of Ewing's Sarcoma. Sarcoma. 2011;2011. pii: 276463. doi: 10.1155/2011/276463.
[28] Houghton J, Stoicov C, Nomura S, et al. Gastric cancer originating from bone marrow-derived cells. Science. 2004; 306(5701): 1568-1571.
[29] Martinez-Lostao L, Marzo I, Anel A, et al. Targeting the Apo2L/TRAIL system for the therapy of autoimmune diseases and cancer. Biochem Pharmacol. 2012; 83(11): 1475-1483.
[30] Sun XY, Nong J, Qin K, et al. MSC(TRAIL)-mediated HepG2 cell death in direct and indirect co-cultures. Anticancer Res. 2011;31(11): 3705-3712.
[31] Liu Z, Ma H, Shi J, et al. Killing effects of controllable expression of tumor necrosis factor-related apoptosis-inducing ligand from mesenchymal stem cells on hepatocellular carcinoma cells. Zhonghua Yi Xue Za Zhi. 2011;91(8):544-548.
[32] Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer. 2008;8(5): 387-398.
[33] Iglesias-Bartolome R, Gutkind JS. Signaling circuitries controlling stem cell fate: to be or not to be. Curr Opin Cell Biol. 2011;23(6): 716-723.
[34] Muncan V, Sansom OJ, Tertoolen L, et al. Rapid loss of intestinal crypts upon conditional deletion of the Wnt/Tcf-4 target gene c-Myc. Mol Cell Biol. 2006;26(22): 8418-8426.
[35] Qiao L, Xu Z, Zhao T, et al. Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model. Cell Res. 2008;18(4): 500-507.
[36] Abdel AM, El AM, Atta HM, et al. Efficacy of mesenchymal stem cells in suppression of hepatocarcinorigenesis in rats: possible role of Wnt signaling. J Exp Clin Cancer Res. 2011; 30: 49.
[37] Li GC, Ye QH, Dong QZ, et al. Mesenchymal stem cells seldomly fuse with hepatocellular carcinoma cells and are mainly distributed in the tumor stroma in mouse models. Oncol Rep. 2013;29(2): 713-719.
[38] Qiao L, Zhao TJ, Wang FZ, et al. NF-kappaB downregulation may be involved the depression of tumor cell proliferation mediated by human mesenchymal stem cells. Acta Pharmacol Sin. 2008;29(3): 333-340.
[39] 陈双庆,王培军,李铭华,等.磁标记骨髓间充质干细胞对肝细胞癌的抑制作用[J].临床放射学杂志, 2009, 28(10): 1454-1458.
[40] 王红梅,赵秀娟,乔振华. 晚期肝癌化疗结合骨髓间充质干细胞输注疗效观察[J].临床医药实践, 2009, 18(5): 327-329.
[41] Furst G, Schulte AEJ, Poll LW, et al. Portal vein embolization and autologous CD133+ bone marrow stem cells for liver regeneration: initial experience. Radiology. 2007;243(1): 171-179.
[42] Stappenbeck TS, Miyoshi H. The role of stromal stem cells in tissue regeneration and wound repair. Science. 2009;324 (5935): 1666-1669.
[43] Li GC, Ye QH, Xue YH, et al. Human mesenchymal stem cells inhibit metastasis of a hepatocellular carcinoma model using the MHCC97-H cell line. Cancer Sci. 2010 ;101(12): 2546-2553.
[44] Yan XL, Jia YL, Chen L, et al. Hepatocellular carcinoma-associated mesenchymal stem cells promote hepatocarcinoma progression: Role of the S100A4-miR155- SOCS1-MMP9 axis. Hepatology. 2013.
[45] 周佳美,向慧玲,朱争艳,等.大鼠骨髓间充质干细胞条件培养基对大鼠肝癌细胞系CBRH-7919增殖能力的影响[J].天津医科大学学报,2011,17(4): 455-458.
[46] Chen XC, Wang R, Zhao X, et al. Prophylaxis against carcinogenesis in three kinds of unestablished tumor models via IL12-gene-engineered MSCs. Carcinogenesis. 2006; 27(12): 2434-2441.
[47] Niess H, Bao Q, Conrad C, et al. Selective targeting of genetically engineered mesenchymal stem cells to tumor stroma microenvironments using tissue-specific suicide gene expression suppresses growth of hepatocellular carcinoma. Ann Surg. 2011;254(5): 767-774, 774-775. |